MK 0852

Known as: MK 852, MK-852, MK-0852 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1993-2003
02419932003

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2003
2003
This study was to investigate the appearance of P-selectin, tissue factor (TF) and CD40 ligand (CD40L) on platelet-leucocyte… (More)
Is this relevant?
2001
2001
Antibody-derived GPIIb-IIIa antagonists, such as the c7E3 Fab fragment abciximab, have been shown to inhibit platelet… (More)
Is this relevant?
1998
1998
A critical function of fibrinogen in hemostasis and thrombosis is to mediate platelet aggregation by binding selectively to an… (More)
  • figure 2
  • figure 1
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
1998
1998
BACKGROUND Citrated platelet-rich plasma (PRP) turbidimetry is used for assessing pharmacodynamic effects of glycoprotein (GP… (More)
  • figure 1
  • figure 2
  • table 2
  • table 1
Is this relevant?
1998
1998
Platelets in stirred whole blood can be induced to form aggregates and also to form heterotypic platelet-monocyte (P/M) and… (More)
Is this relevant?
1998
1998
Conformational activation of platelet GpIIb/IIIa which is coupled to increased affinity for binding of soluble fibrinogen is an… (More)
Is this relevant?
1995
1995
BACKGROUND Thrombin inhibitors have been shown to be efficacious in animal models of thrombosis and in initial human clinical… (More)
Is this relevant?
1994
1994
MK-852 is a newly developed low molecular weight inhibitor of fibrinogen binding to platelets. Platelet aggregation and adhesion… (More)
Is this relevant?
1993
1993
The antiaggregatory and antithrombotic actions of MK-0852, a cyclic heptapeptide antagonist of the platelet GP IIb/IIIa, were… (More)
Is this relevant?